WASHINGTON: People who received the Covid-19 vaccine by Pfizer and Moderna up to 91 percent less likely to develop disease, according to US research which also shows that prevention reduces the severity of symptoms and duration of those who still get infection.
This research, published in the New England Journal of Medicine on June 30, is the first to show the benefits of MRNA vaccines even among those who experienced a breakthrough infection – testing positive immunization.
MRNA vaccines by Pfizer and Moderna contain genetic instructions for our cells to make SARS-COV-2 surge proteins, which are used by viruses to infect and enter human cells.
Our immune system then builds immune responses to surge proteins, and learn how to fight Coronavirus if we meet in the future.
“One of the unique things about this research is that he measures the secondary benefits of the vaccine,” said the Berang Yoon’s study writer, a professor assistant at Utah University, USA.
This study was designed to measure the risk and level of infection between the front lines of pandemics – doctors, nurses, and respondents first.
“These are people who get exposure on virus days in and throughout the day, and vaccines protect them from making diseases.
Those who unfortunately got Covid-19 although vaccinated is still better than those who don’t,” he added.
The study found that the MRNA Covid-19 vaccine was 91 percent effective in reducing the risk of infection as the participant was “fully” vaccinated, two weeks after the second dose.
The researchers also found that vaccines were 81 percent effective in reducing the risk of infection after “partial” immunization, two weeks after the first dose was given.
This study recruited 3,975 participants at eight sites in the US.
Participants sent samples for Covid-19 testing every week for 17 weeks between December 13, 2020 and April 10, 2021.
Only 204 (5 percent) of the participants were finally tested positive for SARS-COV-2, the virus which caused Covid19.
Of these, 156 is not vaccinated, 32 has an uncertain status of vaccines, and 16 fully vaccinated or partially vaccinated.
Participants who are fully vaccinated or some who develop breakthroughs have symptoms that are lighter than those who are not vaccinated.
In those who developed a breakthrough infection, the presence of fever was reduced by 58 percent percent among people who were vaccinated, and the days spent in the bed were reduced by 60 percent.
Virus detection decreases 70 percent percent among those who have an infection breakthrough, from 8.9 days to 2.7 days.
These findings also show that individuals who are fully vaccinated or some who get Covid-19 may be less likely to spread the virus to others.
The researchers found that infected research participants who had been fully or partially vaccinated when infected had a 40 percent virus detected in the nose and did it for six days less than those who were not vaccinated.
“I hope this finding will convince the public that the MRNA Covid-19 vaccine is safe and protects us from this severe disease,” Yoon added.